For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

Mounjaro has become popular as a weight loss drug but it also seems to be linked to hair loss in some cases in a worrying new ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Lilly now plans to file for approval to add the heart failure indication to the label for tirzepatide, which is already sold as Mounjaro for type 2 diabetes and Zepbound for obesity, later this year.

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.